Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia. A randomized controlled trial

Approximately 0.7% of the general population is homozygous for the ɛ2 allele in the APOE gene.1 Since about 10-18% of these ɛ2ɛ2 individuals develop the specific dysbetalipoproteinemia phenotype,2,3 the estimated prevalence of familial dysbetalipoproteinemia (FD) is 1 in 850 to 3500 individuals, making FD the second most common monogenic lipid disorder after fam ilial hypercholesterolemia.4 FD is associated with a very high risk of cardiovascular disease (CVD), due to accumulation of atherogenic cholesterol-enriched triglyceride-rich lipoproteins (TRLs) and generally displays a (very) low concentration of low-density lipoprotein cholesterol (LDL-C).

Source: Journal of Clinical Lipidology - July 21, 2023 Category: Lipidology Authors: Britt E. Heidemann, A. David Marais, Monique T. Mulder, Frank L.J. Visseren, Jeanine E. Roeters van Lennep, Erik S.G. Stroes, Niels P. Riksen, Leonie C. van Vark – van der Zee, Dee M. Blackhurst, Charlotte Koopal Tags: Original Research Source Type: research